\
&
Contact us
\
&
Contact us
Published on | 2 months ago
Programmes Health AI ContinentThe Commission has launched COMPASS-AI – a new initiative that includes the establishment of a community of experts to advance the safe and effective use of artificial intelligence (AI) in healthcare.
This is one of the flagship measures in the Commission’s recent Apply AI Strategy. The initiative aims to promote the responsible and effective integration of AI into clinical settings.
It will focus, in particular, on two priority areas: cancer care and healthcare in remote areas.The initiative intends to launch an interactive digital platform to map best practices and facilitate knowledge exchange, to deliver AI deployment guidelines and to raise AI literacy in the health sector.
More information can be found in the Commission's press release.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
